The impact of malaria coinfection on Ebola virus disease outcomes: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
01
2021
accepted:
13
04
2021
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Viral outbreaks present a particular challenge in countries in Africa where there is already a high incidence of other infectious diseases, including malaria which can alter immune responses to secondary infection. Ebola virus disease (EVD) is one such problem; understanding how Plasmodium spp. and Ebolavirus (EBOV) interact is important for future outbreaks. We conducted a systematic review in PubMed and Web of Science to find peer-reviewed papers with primary data literature to determine 1) prevalence of EBOV/Plasmodium spp. coinfection, 2) effect of EBOV/Plasmodium spp. coinfection on EVD pathology and the immune response, 3) impact of EBOV/Plasmodium spp. coinfection on the outcome of EVD-related mortality. Random effects meta-analyses were conducted with the R package meta to produce overall proportion and effect estimates as well as measure between-study heterogeneity. From 322 peer-reviewed papers, 17 were included in the qualitative review and nine were included in a meta-analysis. Prevalence of coinfection was between 19% and 72%. One study reported significantly lower coagulatory response biomarkers in coinfected cases but no difference in inflammatory markers. Case fatality rates were similar between EBOV(+)/Pl(+) and EBOV(+)/Pl(-) cases (62.8%, 95% CI 49.3-74.6 and 56.7%, 95% CI 53.2-60.1, respectively), and there was no significant difference in risk of mortality (RR 1.09, 95% CI 0.90-1.31) although heterogeneity between studies was high. One in vivo mouse model laboratory study found no difference in mortality by infection status, but another found prior acute Plasmodium yoeli infection was protective against morbidity and mortality via the IFN-γ signalling pathway. The literature was inconclusive; studies varied widely and there was little attempt to adjust for confounding variables. Laboratory studies may present the best option to answer how pathogens interact within the body but improvement in data collection and analysis and in diagnostic methods would aid patient studies in the future.
Identifiants
pubmed: 34029352
doi: 10.1371/journal.pone.0251101
pii: PONE-D-21-03286
pmc: PMC8143409
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0251101Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Microbiol. 2019 Aug 26;57(9):
pubmed: 31315955
Ethiop Med J. 1999 Jul;37(3):173-9
pubmed: 11957314
Lancet. 2005 Jan 15-21;365(9455):233-40
pubmed: 15652606
Sci Rep. 2020 Jul 29;10(1):12765
pubmed: 32728145
J Infect Dis. 2017 Jan 1;215(1):64-69
pubmed: 27226206
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
PLoS Negl Trop Dis. 2017 Feb 2;11(2):e0005265
pubmed: 28151955
N Engl J Med. 2003 Dec 18;349(25):2416-22
pubmed: 14681507
Infect Immun. 2008 Nov;76(11):5149-57
pubmed: 18710867
Infect Dis Poverty. 2019 Jun 15;8(1):49
pubmed: 31200765
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Med Mal Infect. 2014 Dec;44(11-12):491-4
pubmed: 25391486
JCI Insight. 2017 Mar 23;2(6):e88864
pubmed: 28352651
Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5789-94
pubmed: 19297619
Lancet Infect Dis. 2017 Jun;17(6):654-660
pubmed: 28258817
N Engl J Med. 2016 Jan 7;374(1):23-32
pubmed: 26735991
PLoS Pathog. 2014 May 01;10(5):e1004049
pubmed: 24787713
Clin Vaccine Immunol. 2015 May;22(5):477-83
pubmed: 25716232
Res Rep Trop Med. 2018 Jul 27;9:123-136
pubmed: 30100779
Nat Commun. 2018 Sep 25;9(1):3905
pubmed: 30254309
Cell Rep. 2020 Mar 24;30(12):4041-4051.e4
pubmed: 32209467
Int J Epidemiol. 2020 Jun 1;49(3):717-726
pubmed: 32086938
Malar J. 2018 Jun 8;17(1):228
pubmed: 29884184
mSphere. 2017 Aug 23;2(4):
pubmed: 28861524
Global Health. 2016 Sep 13;12(1):53
pubmed: 27624088
Clin Microbiol Rev. 2018 Jul 5;31(4):
pubmed: 29976554
Int J Surg. 2020 Apr;76:71-76
pubmed: 32112977
J Evid Based Med. 2016 May;9(2):91-97
pubmed: 26924387
Clin Infect Dis. 2016 Oct 15;63(8):1026-33
pubmed: 27531847
Emerg Infect Dis. 2016 Feb;22(2):323-6
pubmed: 26814608
J Immunol. 2007 Jul 1;179(1):162-71
pubmed: 17579034
Open Forum Infect Dis. 2019 May 24;6(7):ofz250
pubmed: 31281856
BMC Med Res Methodol. 2014 Feb 18;14:25
pubmed: 24548571
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Am J Phys Med Rehabil. 2020 Jul;99(7):583-585
pubmed: 32427600
Am J Trop Med Hyg. 1996 Jun;54(6):613-9
pubmed: 8686780
Clin Infect Dis. 2017 Feb 1;64(3):243-249
pubmed: 28011610
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Malar J. 2016 Sep 15;15:470
pubmed: 27628178
Glob Health Sci Pract. 2016 Sep 29;4(3):394-409
pubmed: 27688716
J Infect Dis. 2016 Oct 15;214(suppl 3):S250-S257
pubmed: 27638946
Lancet Infect Dis. 2016 Jun;16(6):e82-e91
pubmed: 27020309
PLoS One. 2015 Jun 24;10(6):e0129333
pubmed: 26107529
PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005356
pubmed: 28231242
Clin Infect Dis. 2017 Oct 30;65(10):1769-1770
pubmed: 29020315
Adv Parasitol. 2006;62:293-343
pubmed: 16647974
BMJ. 2007 Nov 3;335(7626):914-6
pubmed: 17974687
J Infect Dis. 2018 Nov 22;218(suppl_5):S434-S437
pubmed: 29878224
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120